Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus

Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus

Background : Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces hyperglycemia and body weight by inhibiting renal glucose reabsorption. However, only a few studies have demonstrated efficacy of dapagliflozin for type 2 diabetic patients in Korea. We evaluated the efficacy and safety...

Full description

Bibliographic Details
Main Authors: Hyun A Cho, Young Lee Jung, Yong Hoon Lee, Yu Chang Lee, Jung Eun Lee, Sol Jae Lee, Su Jin Jeong, Chong Hwa Kim
Format: Article
Language:English
Published: Korean Society for the Study of Obesity 2017-06-01
Series:Journal of Obesity & Metabolic Syndrome
Subjects:
SGLT2 inhibitor
Dapagliflozin
Body weight reduction
Online Access:https://doi.org/10.7570/jomes.2017.26.2.107

Internet

https://doi.org/10.7570/jomes.2017.26.2.107

Similar Items